InvestorLink, having provided more than $2 billion of retail liquidity support to nearly 800 IPOs and follow-on offerings, unveils its new broker-neutral, product-neutral workflow technology platform.
–InvestorLink, a leading retail liquidity venue and workflow technology solution for sell-side investment banks, announces the launch and roll out of its platform delivering end-to-end capabilities to seamlessly source retail liquidity for primary market transactions.
InvestorLink is focused on providing workflow technology that enables syndicate desks to efficiently source retail liquidity for primary market transactions across InvestorLink’s network of over 7,000 retail brokers and financial advisors managing more than $260 billion of assets.
“We founded Investorlink after witnessing the friction that occurred when sourcing and aggregating retail liquidity for primary market transactions. Since then, we’ve supported nearly 800 IPOs and follow-ons and have worked to remove the pain points of our buyside and sell-side stakeholders,” says Matt Michel, Founder and Managing Partner of InvestorLink. “It was this experience that guided us to reinvest in our stakeholder ecosystem to build a broker-neutral, product-neutral technology platform to make this aspect of markets scalable, efficient, and frictionless.”
Investment banks working with InvestorLink can access the firm’s retail network through its digitized platform that can also automate and manage many pre- and post-trade services, including communications and compliance.
Memecoin season is gaining momentum, with Floki, dogwifhat, and KangaMoon leading the charge across social media, showcasing significant price increases and promising growth potential.
Memecoin...
Focused on Identifying Outcomes and Products to Improve ADHD Care, Session Spotlighted the Medical Necessity of Objective Testing for ADHDHOUSTON--(BUSINESS WIRE)--The ADHD Expert Consortium,...
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location
RFS Was 100% in Patients who...